In general, through the regulation of gut microbes and their related metabolites, ginsenoside Rh4 has treated NAFLD through the FXR signaling pathway, thus providing a new therapeutic idea for targeting the gut–liver axis in treating NAFLD. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.